Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase
II
, Randomized,
Double‐Blind
,
Placebo‐Controlled
Trial
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 75, Issue 2, Pages 242-252
Publisher
Wiley
Online
2022-11-12
DOI
10.1002/art.42391
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
- (2022) Eric F Morand et al. Lancet Rheumatology
- Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
- (2022) Ian N Bruce et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
- (2022) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinician-reported outcome measures in lupus trials: a problem worth solving
- (2021) Kathryn Connelly et al. Lancet Rheumatology
- Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls
- (2020) Irene E M Bultink et al. RHEUMATOLOGY
- Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
- (2020) Fabio Basta et al. Rheumatology and Therapy
- Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus
- (2019) Chanakya Sharma et al. ARTHRITIS CARE & RESEARCH
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- (2019) Eric F. Morand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus
- (2017) Hong Dai et al. JOURNAL OF IMMUNOLOGY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- A critical review of clinical trials in systemic lupus erythematosus
- (2016) M A Mahieu et al. LUPUS
- Systemic lupus erythematosus
- (2016) Arvind Kaul et al. Nature Reviews Disease Primers
- Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
- (2015) Kate Franklyn et al. ANNALS OF THE RHEUMATIC DISEASES
- A Novel Technology for Multiplex Gene Expression Analysis Directly from Whole Blood Samples Stabilized at Ambient Temperature Using an RNA-Stabilizing Buffer
- (2015) Chang Hee Kim et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
- (2014) Ian N Bruce et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
- (2013) Daniel J Wallace et al. ANNALS OF THE RHEUMATIC DISEASES
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
- (2012) Michelle Petri et al. ARTHRITIS AND RHEUMATISM
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Cutaneous Lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Instrument
- (2010) Rachel S. Klein et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Novel evidence-based systemic lupus erythematosus responder index
- (2009) Richard A. Furie et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now